Role of Oxidative Stress and Antioxidant Supplementation in Male Fertility.

Nearly 15% of couples experience infertility as a universal health issue. About 50% of infertility cases have been known to be associated with the male partner . Oxidative stress (OS) represents an imbalance in the level of reactive oxygen species (ROS) and anti-oxidants. In fact, OS has been considered as one of the popular pathologies reported in about 50% of all infertile males. Therefore, the increased level of ROS may result in infertility via DNA damages or lipid peroxidation (LPO) as well as the inactivation of enzymes and oxidation of protiens in spermatozoa. Basically, OS results from lifestyle variables. As the absence of antioxidants and the respective deficiencies in the semen cause OS, variations in the lifestyle and anti-oxidant regimes may be advantageous to treatment strategies for resolving such an issue. Actually, anti-oxidants like vitamins E and C, glutathione, coenzyme-Q10, carnitines, selenium, Nacetylcysteine, carotenoids, zinc, and pentoxifylline decline the OS-induced sperm damages. Therefore, the present review overviews the oxidative biochemistry associated with sperm health and identifies which men would be most at risk of oxidative infertility. Hence, the review would show the techniques provided to diagnose OS and diverse therapeutic options.

Limb-girdle Muscular Dystrophy and Therapy: Insights into Cell and Gene-based Approaches.

The Limb-Girdle Muscular Dystrophies (LGMD) are genetically heterogeneous disorders, responsible for muscle wasting and severe form of dystrophies. Despite the critical developments in the insight and information of pathomechanisms of limb-girdle muscular dystrophy, any definitive treatments do not exist, and current strategies are only based on the improvement of the signs of disorder and to enhance the life quality without resolving an underlying cause. There is a crucial relationship between pharmacological therapy and different consequences; therefore, other treatment strategies will be required. New approaches, such as gene replacement, gene transfer, exon skipping, siRNA knockdown, and anti-myostatin therapy, which can target specific cellular or molecular mechanism of LGMD, could be a promising avenue for the treatment. Recently, genome engineering strategies with a focus on molecular tools such as CRISPR-Cas9 are used to different types of neuromuscular disorders and show the highest potential for clinical translation of these therapies. Thus, recent advancements and challenges in the field will be reviewed in this paper.